Inhibiting Aggregation of α-Synuclein with Human Single Chain Antibody Fragments

Sharareh Emadi, Ruitian Liu, Bin Yuan, Philip Schulz, Chad McAllister, Yuri L Lyubchenko, Anne Messer, Michael R. Sierks

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

The α-synuclein protein has been strongly correlated with Parkinson's disease (PD) and is a major component of the hallmark Lewy body aggregates associated with PD. Two different mutations in the α-synuclein gene as well as increased gene dosage of wild-type α-synuclein all associate with early onset cases of PD; and transgenic animal models overexpressing α-synuclein develop PD symptoms. α-Synuclein, a natively unfolded protein, can adopt a number of different folded conformations including a β-sheet form that facilitates formation of numerous aggregated morphologies, including long fibrils, spherical and linear protofibrils, and smaller aggregates or oligomers. The roles of the various morphologies of α-synuclein in the progression of PD are not known, and different species have been shown to be toxic. Here we show that single chain antibody fragments (scFv's) isolated from naïve phage display antibody libraries can be used to control the aggregation of α-synuclein. We isolated an scFv with nanomolar affinity for monomeric α-synuclein (KD = 2.5 × 10-8 M). When co-incubated with monomeric α-synuclein, the scFv decreased not only the rate of aggregation of α-synuclein, but also inhibited the formation of oligomeric and protofibrillar structures. The scFv binds the carboxyl terminal region of α-synuclein, suggesting that perturbation of this region can influence folding and aggregation of α-synuclein in vitro along with the previously identified hydrophobic core region of α-synuclein (residues 61-95, particularly residues 71-82). Since the scFv has been isolated from an antibody library based on human gene sequences, such scFv's can have potential therapeutic value in controlling aggregation of α-synuclein in vivo when expressed intracellularly as intrabodies in dopaminergic neurons.

Original languageEnglish (US)
Pages (from-to)2871-2878
Number of pages8
JournalBiochemistry
Volume43
Issue number10
DOIs
StatePublished - Mar 16 2004

Fingerprint

Synucleins
Single-Chain Antibodies
Immunoglobulin Fragments
Agglomeration
Parkinson Disease
Genes
Intrinsically Disordered Proteins
Lewy Bodies
Genetically Modified Animals
Bacteriophages
Gene Dosage
Antibodies
Poisons
Dopaminergic Neurons

ASJC Scopus subject areas

  • Biochemistry

Cite this

Emadi, S., Liu, R., Yuan, B., Schulz, P., McAllister, C., Lyubchenko, Y. L., ... Sierks, M. R. (2004). Inhibiting Aggregation of α-Synuclein with Human Single Chain Antibody Fragments. Biochemistry, 43(10), 2871-2878. https://doi.org/10.1021/bi036281f

Inhibiting Aggregation of α-Synuclein with Human Single Chain Antibody Fragments. / Emadi, Sharareh; Liu, Ruitian; Yuan, Bin; Schulz, Philip; McAllister, Chad; Lyubchenko, Yuri L; Messer, Anne; Sierks, Michael R.

In: Biochemistry, Vol. 43, No. 10, 16.03.2004, p. 2871-2878.

Research output: Contribution to journalArticle

Emadi, S, Liu, R, Yuan, B, Schulz, P, McAllister, C, Lyubchenko, YL, Messer, A & Sierks, MR 2004, 'Inhibiting Aggregation of α-Synuclein with Human Single Chain Antibody Fragments', Biochemistry, vol. 43, no. 10, pp. 2871-2878. https://doi.org/10.1021/bi036281f
Emadi, Sharareh ; Liu, Ruitian ; Yuan, Bin ; Schulz, Philip ; McAllister, Chad ; Lyubchenko, Yuri L ; Messer, Anne ; Sierks, Michael R. / Inhibiting Aggregation of α-Synuclein with Human Single Chain Antibody Fragments. In: Biochemistry. 2004 ; Vol. 43, No. 10. pp. 2871-2878.
@article{1ef5450a9cc64fd1b5aeef82d57eb137,
title = "Inhibiting Aggregation of α-Synuclein with Human Single Chain Antibody Fragments",
abstract = "The α-synuclein protein has been strongly correlated with Parkinson's disease (PD) and is a major component of the hallmark Lewy body aggregates associated with PD. Two different mutations in the α-synuclein gene as well as increased gene dosage of wild-type α-synuclein all associate with early onset cases of PD; and transgenic animal models overexpressing α-synuclein develop PD symptoms. α-Synuclein, a natively unfolded protein, can adopt a number of different folded conformations including a β-sheet form that facilitates formation of numerous aggregated morphologies, including long fibrils, spherical and linear protofibrils, and smaller aggregates or oligomers. The roles of the various morphologies of α-synuclein in the progression of PD are not known, and different species have been shown to be toxic. Here we show that single chain antibody fragments (scFv's) isolated from na{\"i}ve phage display antibody libraries can be used to control the aggregation of α-synuclein. We isolated an scFv with nanomolar affinity for monomeric α-synuclein (KD = 2.5 × 10-8 M). When co-incubated with monomeric α-synuclein, the scFv decreased not only the rate of aggregation of α-synuclein, but also inhibited the formation of oligomeric and protofibrillar structures. The scFv binds the carboxyl terminal region of α-synuclein, suggesting that perturbation of this region can influence folding and aggregation of α-synuclein in vitro along with the previously identified hydrophobic core region of α-synuclein (residues 61-95, particularly residues 71-82). Since the scFv has been isolated from an antibody library based on human gene sequences, such scFv's can have potential therapeutic value in controlling aggregation of α-synuclein in vivo when expressed intracellularly as intrabodies in dopaminergic neurons.",
author = "Sharareh Emadi and Ruitian Liu and Bin Yuan and Philip Schulz and Chad McAllister and Lyubchenko, {Yuri L} and Anne Messer and Sierks, {Michael R.}",
year = "2004",
month = "3",
day = "16",
doi = "10.1021/bi036281f",
language = "English (US)",
volume = "43",
pages = "2871--2878",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "10",

}

TY - JOUR

T1 - Inhibiting Aggregation of α-Synuclein with Human Single Chain Antibody Fragments

AU - Emadi, Sharareh

AU - Liu, Ruitian

AU - Yuan, Bin

AU - Schulz, Philip

AU - McAllister, Chad

AU - Lyubchenko, Yuri L

AU - Messer, Anne

AU - Sierks, Michael R.

PY - 2004/3/16

Y1 - 2004/3/16

N2 - The α-synuclein protein has been strongly correlated with Parkinson's disease (PD) and is a major component of the hallmark Lewy body aggregates associated with PD. Two different mutations in the α-synuclein gene as well as increased gene dosage of wild-type α-synuclein all associate with early onset cases of PD; and transgenic animal models overexpressing α-synuclein develop PD symptoms. α-Synuclein, a natively unfolded protein, can adopt a number of different folded conformations including a β-sheet form that facilitates formation of numerous aggregated morphologies, including long fibrils, spherical and linear protofibrils, and smaller aggregates or oligomers. The roles of the various morphologies of α-synuclein in the progression of PD are not known, and different species have been shown to be toxic. Here we show that single chain antibody fragments (scFv's) isolated from naïve phage display antibody libraries can be used to control the aggregation of α-synuclein. We isolated an scFv with nanomolar affinity for monomeric α-synuclein (KD = 2.5 × 10-8 M). When co-incubated with monomeric α-synuclein, the scFv decreased not only the rate of aggregation of α-synuclein, but also inhibited the formation of oligomeric and protofibrillar structures. The scFv binds the carboxyl terminal region of α-synuclein, suggesting that perturbation of this region can influence folding and aggregation of α-synuclein in vitro along with the previously identified hydrophobic core region of α-synuclein (residues 61-95, particularly residues 71-82). Since the scFv has been isolated from an antibody library based on human gene sequences, such scFv's can have potential therapeutic value in controlling aggregation of α-synuclein in vivo when expressed intracellularly as intrabodies in dopaminergic neurons.

AB - The α-synuclein protein has been strongly correlated with Parkinson's disease (PD) and is a major component of the hallmark Lewy body aggregates associated with PD. Two different mutations in the α-synuclein gene as well as increased gene dosage of wild-type α-synuclein all associate with early onset cases of PD; and transgenic animal models overexpressing α-synuclein develop PD symptoms. α-Synuclein, a natively unfolded protein, can adopt a number of different folded conformations including a β-sheet form that facilitates formation of numerous aggregated morphologies, including long fibrils, spherical and linear protofibrils, and smaller aggregates or oligomers. The roles of the various morphologies of α-synuclein in the progression of PD are not known, and different species have been shown to be toxic. Here we show that single chain antibody fragments (scFv's) isolated from naïve phage display antibody libraries can be used to control the aggregation of α-synuclein. We isolated an scFv with nanomolar affinity for monomeric α-synuclein (KD = 2.5 × 10-8 M). When co-incubated with monomeric α-synuclein, the scFv decreased not only the rate of aggregation of α-synuclein, but also inhibited the formation of oligomeric and protofibrillar structures. The scFv binds the carboxyl terminal region of α-synuclein, suggesting that perturbation of this region can influence folding and aggregation of α-synuclein in vitro along with the previously identified hydrophobic core region of α-synuclein (residues 61-95, particularly residues 71-82). Since the scFv has been isolated from an antibody library based on human gene sequences, such scFv's can have potential therapeutic value in controlling aggregation of α-synuclein in vivo when expressed intracellularly as intrabodies in dopaminergic neurons.

UR - http://www.scopus.com/inward/record.url?scp=1542357652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542357652&partnerID=8YFLogxK

U2 - 10.1021/bi036281f

DO - 10.1021/bi036281f

M3 - Article

VL - 43

SP - 2871

EP - 2878

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 10

ER -